Compare Allstate Corp (ALL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs Novo Nordisk A/S — how do they compare? Allstate Corp trades at $260.97 (market cap $66.31B), while Novo Nordisk A/S trades at $45.98 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 3.1× Allstate Corp's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| ALL | NVO | |
|---|---|---|
Market Cap | $66.31B | $207.85B |
Sector | Financials | Health |
52-Week High | $275.11 | $63.98 |
52-Week Low | $190.00 | $35.29 |
Enterprise Value | $74.96B | $222.55B |
Dividend Yield | 1.65% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $269.67, up 1.0% today, near its 52-week high. The stock shows bullish technical signals with strong support at $267. Fundamentally, the company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, with revenue growth and improved underwriting profitability. The P/E ratio of 5.25 indicates attractive valuation relative to earnings. Recent news highlights strong operational performance but questions sustainability.
Outlook is positive with earnings beats and dividend payments, but risks include potential normalization of underwriting margins and competitive pressures. Analyst consensus is mixed with a $266.47 price target, suggesting limited upside from current levels. Investment appeal lies in valuation and profitability, though sustainability concerns warrant caution.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
